Neogenomics shares jump 10.42% premarket as focus on oncology diagnostics and precision medicine drives investor interest.

NeoGenomics surged 10.42% in premarket trading following a report highlighting its pivotal role in the oncology diagnostics sector, emphasizing its comprehensive laboratory services for cancer diagnosis and treatment. The article underscored NeoGenomics’ leadership in precision medicine and its alignment with rising cancer incidence and demand for advanced genetic testing. This positioning, combined with its established infrastructure and expansion potential in genetic profiling, appears to have bolstered investor sentiment, driving the strong premarket gain.